Disclosed herein is a novel use of a triterpenoid mixture for the treatment of multiple sclerosis (MS). The triterpenoid mixture consists of, ganoderic acid A (GAA), ganoderic acid B (GAB), ganoderic acid C (GAC), ganoderic acid C5 (GAC5), ganoderic acid C6 (GAC6), ganoderic acid D (GAD), ganoderic acid E (GAE), ganoderic acid G (GAG), and ganoderenic acid D. The triterpenoid mixture may be administered to a subject suffering from MS in a dose of about 1 to 10 mg/Kg to ameliorate or alleviate symptoms associated with MS.